Blueprint Medicines (BPMC) Receives a Buy from Wedbush
Wedbush analyst David Nierengarten maintained a Buy rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $128.00.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Nierengarten covers the Healthcare sector, focusing on stocks such as Argenx Se, Scholar Rock Holding, and Oric Pharmaceuticals. According to TipRanks, Nierengarten has an average return of 3.7% and a 37.97% success rate on recommended stocks.
Blueprint Medicines has an analyst consensus of Strong Buy, with a price target consensus of $130.40.
Based on Blueprint Medicines’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $146.37 million and a GAAP net loss of $49.96 million. In comparison, last year the company earned a revenue of $71.96 million and had a GAAP net loss of $110.92 million
Based on the recent corporate insider activity of 70 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Last month, Jeffrey Albers, a Director at BPMC sold 5,766.00 shares for a total of $512,020.80.
Read More on BPMC:
Disclaimer & DisclosureReport an Issue
- Blueprint Medicines: Strong Growth Potential Driven by Ayvakit and Promising Pipeline
- Optimistic Long-Term Growth Potential for Blueprint Medicines Amid Short-Term Revenue Concerns
- JPMorgan healthcare analysts hold an analyst/industry conference call
- Blueprint Medicines: Strong Growth, Strategic M&A Potential, and Promising Pipeline Drive Positive Outlook
- Blueprint Medicines assumed with an Equal Weight at Morgan Stanley
